Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 5/20 | 0.32 |
| ▸ | MMP9 | P14780 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP7 | P09237 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008909 | 1.00 | LMNA (0.39) | LMNAKMT2AMEN1NPSR1MAPT | |
| SCHEMBL2012770 | 0.87 | ELANE (0.40) | LMNANPSR1MAPTALDH1A1KDM4E | |
| SCHEMBL2008561 | 0.87 | LMNA (0.41) | LMNAKMT2AMEN1NPSR1MAPT | |
| SCHEMBL2012767 | 0.87 | ELANE (0.40) | LMNANPSR1MAPTALDH1A1KDM4E | |
| SCHEMBL2008560 | 0.87 | LMNA (0.41) | LMNAKMT2AMEN1NPSR1MAPT | |
| SCHEMBL30547435 | 0.86 | LMNA (0.40) | LMNAKMT2AMEN1NPSR1MAPT | |
| SCHEMBL10004866 | 0.81 | SMN1; SMN2 (0.41) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL10004224 | 0.80 | SMN1; SMN2 (0.40) | LMNAKMT2AMEN1NPSR1MAPT | |
| SCHEMBL10003821 | 0.79 | SMN1; SMN2 (0.40) | KMT2AMEN1NPSR1MAPTMAPK1 | |
| SCHEMBL10004082 | 0.78 | CA1 (0.38) | KMT2AMEN1RAB9ASMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12121529-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-2203462-B2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240139227-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC | 2024-05-02 | — | — | US | disclosed |
| EP-2801580-B1 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-2801580-A1 | Nucleoside phosphoramidate prodrugs | Gilead Pharmasset LLC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20110257122-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7964580-B2 | Nucleoside phosphoramidate prodrugs | PHARMASSET, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100016251-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139227-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | LMNA 2469/4885KMT2A 3532/4885MEN1 2978/4885 |
| US-20100016251-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | LMNA 2469/4885KMT2A 3532/4885MEN1 2978/4885 |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | LMNA 2469/4885KMT2A 3532/4885MEN1 2978/4885 |
| US-20110257122-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | LMNA 2469/4885KMT2A 3532/4885MEN1 2978/4885 |
| US-12121529-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | LMNA 2469/4885KMT2A 3532/4885MEN1 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.